
Investors & Media
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources
Stockholder Tools
News Releases
News Releases
September 28, 2020
MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference
September 22, 2020
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
August 6, 2020
MeiraGTx Reports Second Quarter 2020 Financial Results
August 5, 2020
MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer
July 17, 2020
MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients
May 26, 2020
MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders
May 7, 2020
MeiraGTx Reports First Quarter 2020 Financial Results
May 6, 2020
MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference
March 11, 2020
MeiraGTx Reports Full Year 2019 Financial Results
March 2, 2020
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
Displaying 11 - 20 of 21
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources